Jamieson is pleased to announce that it has advised the management team of Synthon on the sale of the business from BC Partners to Goldman Sachs Alternatives and their reinvestment into the company.
Headquartered in the Netherlands, Synthon is a vertically integrated, global leader in the development and manufacturing of complex generics drugs. Synthon has a global footprint with direct presence in eight countries, including four R&D labs as well as four manufacturing sites located in Spain, Czech Republic, Argentina, and Chile. The company specialises in developing and manufacturing generic versions of complex drugs with a portfolio that includes treatments for cancer, cardiovascular conditions and multiple sclerosis.
Anish Mehta, CEO of Synthon, said: “Jamieson was an important partner and advisor to me and the Synthon management team throughout the sale process. We appreciated the thoughtful and analytical approach, resulting in a good outcome for Management and Goldman Sachs Alternatives”.
Andrew Cox, Stuart Coventry, Pieter Hornsveld, Henry Balcerak and Adam Colley advised the Synthon management team on the transaction and the management incentive terms.
